| Cancer as an evolutionary and ecological process LMF Merlo, JW Pepper, BJ Reid, CC Maley Nature reviews cancer 6 (12), 924-935, 2006 | 1660 | 2006 |
| A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma LMF Merlo, NA Shah, X Li, PL Blount, TL Vaughan, BJ Reid, CC Maley Cancer prevention research 3 (11), 1388-1397, 2010 | 155 | 2010 |
| IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation R Metz, C Smith, JB DuHadaway, P Chandler, B Baban, LMF Merlo, ... International immunology 26 (7), 357-367, 2014 | 140 | 2014 |
| Cancer in light of experimental evolution K Sprouffske, LMF Merlo, PJ Gerrish, CC Maley, PD Sniegowski Current Biology 22 (17), R762-R771, 2012 | 89 | 2012 |
| IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis LMF Merlo, E Pigott, JB DuHadaway, S Grabler, R Metz, GC Prendergast, ... The Journal of Immunology 192 (5), 2082-2090, 2014 | 83 | 2014 |
| IDO2 in immunomodulation and autoimmune disease GC Prendergast, R Metz, AJ Muller, LMF Merlo, L Mandik-Nayak Frontiers in immunology 5, 585, 2014 | 79 | 2014 |
| The role of genetic diversity in cancer LMF Merlo, CC Maley The Journal of clinical investigation 120 (2), 401-403, 2010 | 71 | 2010 |
| Polyploidy, aneuploidy and the evolution of cancer LMF Merlo, JW Pepper, PS Rabinovitch, CC Maley Polyploidization and Cancer, 1-13, 2010 | 38 | 2010 |
| Development and characterization of an organotypic model of Barrett's esophagus RE Kosoff, KL Gardiner, LMF Merlo, K Pavlov, AK Rustgi, CC Maley Journal of cellular physiology 227 (6), 2654-2659, 2012 | 36 | 2012 |
| Therapeutic antibody targeting of indoleamine-2, 3-dioxygenase (IDO2) inhibits autoimmune arthritis LMF Merlo, S Grabler, JB DuHadaway, E Pigott, K Manley, ... Clinical Immunology 179, 8-16, 2017 | 31 | 2017 |
| IDO2 modulates T cell–dependent autoimmune responses through a B cell–intrinsic mechanism LMF Merlo, JB DuHadaway, S Grabler, GC Prendergast, AJ Muller, ... The Journal of Immunology 196 (11), 4487-4497, 2016 | 30 | 2016 |
| IDO2: a pathogenic mediator of inflammatory autoimmunity LMF Merlo, L Mandik-Nayak Clinical Medicine Insights: Pathology 9, CPath. S39930, 2016 | 23 | 2016 |
| An in vitro co-culture model of esophageal cells identifies ascorbic acid as a modulator of cell competition LMF Merlo, RE Kosoff, KL Gardiner, CC Maley BMC cancer 11 (1), 461, 2011 | 20 | 2011 |
| An empirical test of the concomitantly variable codon hypothesis LMF Merlo, M Lunzer, AM Dean Proceedings of the National Academy of Sciences 104 (26), 10938-10943, 2007 | 13 | 2007 |
| The argRB of Escherichia coli is rare in isolates obtained from natural sources LMF Merlo, MJ Sadowsky, JA Ferguson, AM Dean Gene 376 (2), 240-247, 2006 | 4 | 2006 |
| Differential roles of IDO1 and IDO2 in T and B cell inflammatory immune responses LMF Merlo, JB DuHadaway, JD Montgomery, WD Peng, PJ Murray, ... Frontiers in immunology 11, 1861, 2020 | 3 | 2020 |
| Adaptive immunity: B cells and antibodies LMF Merlo, L Mandik-Nayak Cancer Immunotherapy, 25-40, 2013 | 3 | 2013 |
| B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2, 3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model LMF Merlo, J Bowers, T Stefanoni, R Getts, L Mandik-Nayak Clinical Pathology 13, 2632010X20951812, 2020 | 1 | 2020 |
| IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. R Metz, C Smith, JB DuHadaway, P Chandler, B Baban, LMF Merlo, ... International immunology 31 (3), 181-182, 2019 | 1 | 2019 |
| Cancer Immunotherapy: Chapter 3. Adaptive Immunity: B Cells and Antibodies LMF Merlo, L Mandik-Nayak Elsevier Inc. Chapters, 2013 | 1 | 2013 |
